Christopher D. King
Corporate Officer/Principal chez PharmAkea, Inc.
Profil
Christopher D.
King is the founder of Ra Medical Systems, Inc. He is currently the Executive Director-Drug Metabolism at PharmAkea, Inc. His former positions include being a Principal at Johnson & Johnson, Merck & Co., Inc., and Amira Pharmaceuticals, Inc. He received his undergraduate degree from Beloit College, his MBA from California State University-San Marcos, and his doctorate from the University of Iowa.
Postes actifs de Christopher D. King
| Sociétés | Poste | Début |
|---|---|---|
PharmAkea, Inc.
 PharmAkea, Inc. Pharmaceuticals: MajorHealth Technology PharmAkea, Inc. develops small molecule drug candidates against protein targets involved in fibro proliferative diseases. It discovers and develops small molecule therapeutics directed at cancer and fibrotic diseases. The company was founded by John Howard Hutchinson, Kevin Holme, and Jilly Evans in 2012 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Anciens postes connus de Christopher D. King
| Sociétés | Poste | Fin |
|---|---|---|
| CATHETER PRECISION, INC. | Fondateur | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
Amira Pharmaceuticals, Inc.
 Amira Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. The firm's team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and various fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease. | Corporate Officer/Principal | - |
| JOHNSON & JOHNSON | Corporate Officer/Principal | - |
Formation de Christopher D. King
| California State University-San Marcos | Masters Business Admin |
| Beloit College | Undergraduate Degree |
| University of Iowa | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| MERCK & CO., INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
PharmAkea, Inc.
PharmAkea, Inc. Pharmaceuticals: MajorHealth Technology PharmAkea, Inc. develops small molecule drug candidates against protein targets involved in fibro proliferative diseases. It discovers and develops small molecule therapeutics directed at cancer and fibrotic diseases. The company was founded by John Howard Hutchinson, Kevin Holme, and Jilly Evans in 2012 and is headquartered in San Diego, CA. | Health Technology |
Amira Pharmaceuticals, Inc.
Amira Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. The firm's team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and various fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease. | Health Technology |
Ra Medical Systems, Inc.
 Ra Medical Systems, Inc. Medical SpecialtiesHealth Technology Ra Medical Systems, Inc. engages in the design, development and commercialization of excimer lasers for the treatment of vascular immune-mediated inflammatory diseases. Its product, the Destruction of Arteriosclerotic Blockages by laser Radiation Ablation (DABRA) laser and single-use catheter, together referred to as DABRA, is used as a tool in the treatment of peripheral artery disease which commonly occurs in the legs. The company was founded by Dean Irwin and Melissa Burstein on September 4, 2002 and is headquartered in Fort Mill, SC. | Health Technology |
